Mark B. Kaye's Insider Trades & SAST Disclosures
Mark B. Kaye's most recent trade in Conmed Corp. was a trade of 8,061 Options To Purchase Common Stock done . Disclosure was reported to the exchange on June 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark B. Kaye.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Conmed Corp. | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 8,061 | 8,061 | - | - | Options To Purchase Common Stock | |
| Conmed Corp. | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 668 | 668 | - | - | RSUs (Restricted Stock Units) | |
| Elevance Health Inc | Mark B. Kaye | EVP & CFO | Sale of securities on an exchange or to another person at price $ 424.82 per share. | 24 Apr 2025 | 4,588 | 18,977 (0%) | 0% | 424.8 | 1,949,074 | Common Stock |
| Elevance Health Inc | Mark B. Kaye | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 13,713 | 13,713 | - | - | Employee Stock Option (Right to Buy) | |
| Elevance Health Inc | Mark B. Kaye | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 3,604 | 23,565 (0%) | 0% | 0 | Common Stock | |
| Elevance Health Inc | Mark B. Kaye | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 395.50 per share. | 03 Mar 2025 | 270 | 19,961 (0%) | 0% | 395.5 | 106,785 | Common Stock |
| Conmed Corp. | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 1,846 | 1,846 | - | - | Options To Purchase Common Stock | |
| Conmed Corp. | Mark B. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 152 | 152 | - | - | RSUs (Restricted Stock Units) | |
| Elevance Health Inc | Mark B. Kaye | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.16 per share. | 02 Oct 2024 | 2,818 | 20,213 (0%) | 0% | 505.2 | 1,423,541 | Common Stock |
| Elevance Health Inc | Mark Kaye B. | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,633 | 10,633 | - | - | Employee Stock Option (Right to Buy) | |
| Elevance Health Inc | Mark Kaye B. | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 2,755 | 23,031 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges